TGN38A Inhibitors
Chemical inhibitors of TGN38A can disrupt its function through various mechanisms that impede intracellular trafficking processes. Dynasore, for example, targets the GTPase dynamin, which is essential for clathrin-mediated endocytosis, thus directly affecting TGN38A's ability to cycle between the trans-Golgi network and the plasma membrane. Similarly, Pitstop 2 obstructs TGN38A function by blocking clathrin's interaction with adaptor proteins, which is a crucial step in clathrin-mediated endocytosis. Compounds like Brefeldin A and Monensin disrupt Golgi apparatus function, with Brefeldin A causing the disassembly of the Golgi structure and inhibiting vesicular transport between the endoplasmic reticulum and the Golgi, and Monensin altering the pH and ion gradients within the Golgi, both of which are detrimental to TGN38A's processing and trafficking.
Further complicating the intracellular transport of TGN38A are substances that interfere with the cytoskeleton components. Nocodazole and Paclitaxel both impact microtubule dynamics, which are necessary for vesicular transport; however, while Nocodazole causes microtubule depolymerization, Paclitaxel, conversely, stabilizes microtubules to the point where it impedes necessary dynamic changes. Cytochalasin D and Latrunculin A disrupt actin filaments; the former by inhibiting actin polymerization, and the latter by sequestering actin monomers. This compromises actin's role in endocytosis and vesicle movement, affecting TGN38A's distribution in the cell. Other inhibitors like Gö6976, ML-9, Wortmannin, and Genistein target various kinases and signaling pathways. Gö6976 inhibits protein kinase C, ML-9 targets myosin light chain kinase, Wortmannin is an inhibitor of phosphoinositide 3-kinases, and Genistein inhibits tyrosine kinases, all of which are involved in phosphorylation and signaling events that regulate vesicle trafficking and, by extension, the proper functioning of TGN38A.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
Dynasore inhibits dynamin, which is crucial for clathrin-mediated endocytosis, a pathway that TGN38A uses for trafficking between the trans-Golgi network and the plasma membrane. Inhibition of this endocytosis pathway would hinder the functional cycling of TGN38A. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A disrupts the Golgi structure and blocks vesicular traffic between the endoplasmic reticulum and the Golgi apparatus. As TGN38A is involved in trafficking between the Golgi and other cellular compartments, its function would be inhibited by the disruption of this transport pathway. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
Nocodazole disrupts microtubules, which are necessary for vesicular transport between the trans-Golgi network and the plasma membrane. This would inhibit the trafficking of TGN38A within the cell. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
Cytochalasin D inhibits actin polymerization, which is essential for many cellular processes including endocytosis and vesicle movement. By disrupting these processes, the function of TGN38A in vesicle trafficking would be inhibited. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin is an ionophore that disrupts Golgi function by altering the pH and ion gradients. This would inhibit the processing and trafficking of TGN38A through the Golgi apparatus. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $223.00 | 8 | |
Gö6976 is a protein kinase C inhibitor. Since PKC can phosphorylate proteins that regulate vesicular trafficking, inhibiting PKC could potentially hinder the functioning of proteins like TGN38A that are involved in vesicular transport. | ||||||
ML-9 | 105637-50-1 | sc-200519 sc-200519A sc-200519B sc-200519C | 10 mg 50 mg 100 mg 250 mg | $110.00 $440.00 $660.00 $1200.00 | 2 | |
ML-9 is an inhibitor of myosin light chain kinase (MLCK). MLCK activity is involved in cytoskeletal rearrangements necessary for vesicle fusion and transport processes, thus its inhibition could impair the trafficking functions of TGN38A. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). PI3K signaling is involved in the regulation of vesicle trafficking, and its inhibition by wortmannin would disrupt processes in which TGN38A is involved. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor and can inhibit the phosphorylation of proteins involved in intracellular signaling and trafficking. Since TGN38A trafficking relies on phosphorylation events, genistein could inhibit its function. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $260.00 $799.00 | 36 | |
Latrunculin A binds to actin monomers and prevents polymerization, thereby disrupting cytoskeletal dynamics. This would inhibit the trafficking of TGN38A, which depends on an intact actin cytoskeleton. | ||||||